US Patent

US9504666 — Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration

Formulation · Assigned to Sintetica SA · Expires 2033-12-11 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a chloroprocaine-based pharmaceutical composition for repeated intrathecal administration without significantly increasing neurotoxicity.

USPTO Abstract

This invention relates to an injectable pharmaceutical composition based on chloroprocaine or salts and/or derivatives thereof for use in central loco-regional anesthesia by intrathecal administration in repeated doses. Unexpectedly, the intrathecal administration in repeated doses of chloroprocaine does not increase the neurotoxicity of this drug in statistically significant manner.

Drugs covered by this patent

chloroprocaine-hydrochloride (CHLOROPROCAINE HYDROCHLORIDE)

Patent Metadata

Patent number: US9504666
Jurisdiction: US
Classification: Formulation
Expires: 2033-12-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Sintetica SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.